New hope for CLL patients: a drug that may spare the heart
NCT ID NCT06757647
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether acalabrutinib, a drug similar to ibrutinib, is safer for the heart in people with chronic lymphocytic leukemia (CLL). Many patients on ibrutinib develop heart side effects and have to stop treatment. Researchers will give acalabrutinib to 61 adults with CLL who had heart problems on ibrutinib, and use heart MRIs to check if their heart function improves or stays stable. The goal is to find a treatment that controls the cancer without harming the heart.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Acalabrutinib
- What this could lead to
- If successful, this could show that acalabrutinib is a heart-friendlier option for CLL patients who had heart problems with ibrutinib, allowing them to continue effective cancer treatment.
- What could go wrong
- This is a small, early-phase study (61 people) with no control group, so results may not apply broadly. Acalabrutinib may still cause heart issues or not control the cancer as well.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New BTK blocker aims to outsmart drug resistance in elderly CLL patients
- New combo aims to shorten CLL treatment
- New pill shows promise against Hard-to-Treat blood cancers
- New cocktail aims to tame Slow-Growing blood cancers
- Could a cancer drug tame a blood disorder?
- Triple threat: new drug cocktail aims to wipe out CLL/SLL